# Mankind Pharma

> Mankind Pharma is a VC fund backing Artificial Intelligence and EdTech. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New Delhi, India
- Total investments: 9
- Last investment: Jul 2026
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/1629329/
- X (Twitter): https://twitter.com/Pharma_Mankind
- Website: https://www.mankindpharma.com
- Facebook: https://www.facebook.com/MankindPharmalimited

Mankind Pharma is a VC fund in New Delhi focused on Artificial Intelligence and EdTech. Mankind Pharma aspires to aid the community in a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. Mankind Pharma came into existence in 1986, and in 1991, the company was formed into a legal corporation. However, it actively started working as afully-integrated pharmaceutical company in 1995. Today, Mankind has an employee base of over 14,000 and is racing towards $1 Billion.The company takes great pride in the success of its products ranging from Pharma, OTC, and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Adiction, Gas-O-Fast, Kaloree 1 and many others.

## Contacts

5 contacts available for Mankind Pharma. Shizune tracks 5 team members at Mankind Pharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mankind-pharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 2 | 22% |
| EdTech | 1 | 11% |
| Energy | 1 | 11% |
| Mineral | 1 | 11% |
| Organic | 1 | 11% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 33% |
| Seed | 2 | 22% |
| Series B | 2 | 22% |
| Venture - Series Unknown | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 5 | 56% |
| United Kingdom | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ajay Bansal | Marketing Director | 0 | — |
| P.K Arora | Director | 0 | — |
| Rajeev Juneja | CEO | 3 | — |
| R.C Juneja | Chairman, Founder & CEO | 0 | — |
| Sheetal Arora | Managing Director | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BatX Energies | BatX Energies has developed a proprietary Zero Waste–Zero Emission technology to extract critical Rare Earth metals, namely Lithium, Cobalt, Nickel, and Manganese from scrap Lithium-Ion batteries. These critical materials are the key drivers of global electric mobility. | $11M | Series A | Jul 02, 2026 |  |
| Innov8 Coworking | Innov8 Coworking is a Y- Combinator backed workspaces and community startup based in India. They provide premium workspaces (managed private offices and coworking spaces).Innov8 Coworking is the first of its kind Thought space in India. They encourage community engagement of like-minded individuals from any space, whether they are founders,investors, freelancers, creators or just want to work in a highly productive zone.They currently have centers across India - Delhi, Noida, Gurgaon, Mumbai, Bangalore and Chandigarh. | $12.7M | Venture - Series Unknown | Jan 28, 2025 |  |
| Actimed Therapeutics | Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research. | $6M | Series A | Aug 22, 2023 |  |
| Actimed Therapeutics | Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research. | $6.4M | Series A | Jun 26, 2023 |  |
| Actimed Therapeutics | Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research. | $12.1M | Seed | Jan 04, 2023 |  |
| BatX Energies | BatX Energies has developed a proprietary Zero Waste–Zero Emission technology to extract critical Rare Earth metals, namely Lithium, Cobalt, Nickel, and Manganese from scrap Lithium-Ion batteries. These critical materials are the key drivers of global electric mobility. | $1.6M | Seed | Jun 23, 2022 |  |
| Leverage Edu | Leverage Edu is an AI-enabled marketplace designed to help students with their higher education and career growth plans. It is one of India's leading/fastest growing ed-tech companies, transforming access to an exponential career growth, by democratising mentorship, breaking traditional systems, & helping the new student of today jumpover the artificial high walls! | $22M | Series B | Mar 21, 2022 |  |
| Dogsee Chew | Dogsee Chew is formed for the love of dogs. Bhupendra wanted to bring organic foods for dogs - a healthy treat with high protein and less carbs, and he ended up with Dogsee Chew. It is a highly nutritious high quality snacking option for your dogs. | $6.7M | Series A | Jan 19, 2022 |  |
| Miko | Miko is a consumer electronics company founded on the pillars of Robotics, Artificial Intelligence, and the Internet of Things. Miko was founded in January 2015 by three IIT Bombay post-graduates and is today driven by a 120 membered team of roboticists, academicians, and neuropsychologists. The core team of roboticists has been together since2009, making some of the world’s most widely acclaimed robots. Among these are India’s most capable autonomous underwater vehicles, which ranked among the best internationally and performed Navy-based tasks. | $28.8M | Series B | Aug 11, 2021 |  |

9 of 9 investments shown.

## Co-investors
- [IvyCap Ventures](https://shizune.co/investors/profile/ivycap-ventures) — VC Fund, 2 deals together
- [JITO Angel Network](https://shizune.co/investors/profile/jito-angel-network) — VC Fund, 2 deals together
- [100Unicorns](https://shizune.co/investors/profile/9unicorns) — VC Fund, 1 deal together
- [AngelList India](https://shizune.co/investors/profile/angellist-india) — VC Fund, 1 deal together
- [Aroa Venture Partners](https://shizune.co/investors/profile/aroa-ventures) — VC Fund, 1 deal together
- [Artha Group](https://shizune.co/investors/profile/artha-india-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Mankind Pharma invest in?

Mankind Pharma invests primarily in Artificial Intelligence, EdTech and Energy startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mankind Pharma?

Public channels for Mankind Pharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mankind Pharma?

The team at Mankind Pharma includes Ajay Bansal (Marketing Director), P.K Arora (Director) and Rajeev Juneja (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co